CRISPR in Europe: the patent landscape for 2018

The Broad Institute of MIT and Harvard may lose a substantial number of European patent claims covering CRISPR/Cas9, but it has at least one trump card to play before we get to that stage, one European patent attorney has told LSIPR.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

Exclusive: ‘When a UPC judge wears their robe, they have no gender’

9 June 2026 In the second of a series of interviews with women judges at the Unified Patent Court, Carine Gillet shares her views with Sarah Speight on encouraging more women into technical judicial careers, how equipped the court is to handle life sciences disputes, and more.

Europe

UPC dispute resolution forum opens with ceremony in Slovenia

2 June 2026 The court has officially opened its mediation and arbitration forum, with technology, life sciences and manufacturing companies expected to be among its earliest users—particularly in FRAND and licensing cases.

Europe

European court backs AstraZeneca unit in blood cancer combo dispute

28 May 2026 A European court dismissed a challenge by a German generics manufacturer, confirming the validity of a patent covering a blood cancer combination therapy.

More features

US biotech fires trade secrets suit at Chinese pharma group

Hikma v Amarin: Six takeaways from the pivotal ruling

Exclusive: ‘When a UPC judge wears their robe, they have no gender’

Clarivate’s new IP president to ‘usher in next phase of growth’

Fed Circ rejects Nexus’ appeal in generics row with biopharma firm

Ex-Kirkland patent litigator jumps to rival firm

Hikma triumphs at SCOTUS in landmark skinny-label ruling

Pfizer strikes $10.5 billion oncology deal with Chinese biotech

CRISPR in Europe: the patent landscape for 2018

More on this story

Editor's picks

Editor's picks

More features